重组人脑利钠肽治疗急性心肌梗死后失代偿性心力衰竭的临床疗效与安全性

Clinical Curative Effect and Security of Recombinant Human Brain Natriuretic Peptide in Treatment of Acute Decompensated Heart Failure After Myocardial Infarction

目的探讨重组人脑利钠肽治疗急性心梗后失代偿性心力衰竭的临床疗效与安全性。方法选取我院收治的急性心梗后失代偿性心力衰竭患者90例作为研究对象。随机分为观察组与对照组,每组45例,对照组接受常规药物治疗,观察组应用重组人脑利钠肽治疗,比较两组治疗前后血脑钠肽(BNP)、左室射血分数(LVEF)指标及临床预后结局。结果两组治疗前BNP、LVEF值比较差异无统计学意义(P>0.05),治疗后均改善,但观察组BNP、LVEF治疗后改善效果优于对照组(P<0.05);观察组治疗后心功能Killip分级改善优于对照组(P<0.05),但两组30 d病死率以及不良反应发生率比较差异无统计学意义(P>0.05)。结论重组人脑利钠肽治疗急性心梗后失代偿性心力衰竭临床疗效良好,可有效改善患者心功能指标。

Objective To study the recombinant human brain natriuretic peptide in treatment of acute decompensated heart failure after myocardial infarction of clinical curative effect and security.Methods Chose our hospital patients with acute decompensated heart failure after myocardial infarction 90 cases as the research object. Randomly divided into observation group and control group,45 cases in each group. Control group received conventional drug treatment,the use of recombinant human brain natriuretic peptide for observation group, compared two groups before and after treatment the blood brain natriuretic peptide（BNP）,left ventricular ejection fraction（LVEF）and clinical prognosis.Results The two groups before treatment the BNP,LVEF value comparison there was no significant difference（P〉0.05）. After treatment,they were significantly improved,but the BNP,LVEF improve for observation group was obviously better to the control group（P〈0.05）. And Killip classification improved was better than that of control group（P〈0.05）,but the two groups of 30 d mortality and incidence of adverse reactions was no significant difference（P〉0.05）.Conclusion The recombinant human brain natriuretic peptide in treatment of acute decompensated heart failure after myocardial infarction can effectively improve patients with cardiac function index,decrease case fatality rate.